U.S. Markets closed

AVEO Pharmaceuticals, Inc. (AVEO)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.25+0.52 (+71.75%)
At close: 4:00PM EDT
People also watch
PBMDANTHINFIARQLACRX
Full screen
Previous Close0.73
Open1.13
Bid1.20 x 2000
Ask1.27 x 500
Day's Range1.05 - 1.38
52 Week Range0.50 - 1.38
Volume54,894,350
Avg. Volume1,542,664
Market Cap182.06M
Beta1.96
PE Ratio (TTM)-3.29
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MarketWatchyesterday

    AVEO Pharma surges 48% on recommendation for European approval of its cancer drug

    AVEO Pharmaceuticals Inc. shares surged as much as 48% in extremely heavy morning trade Friday after the company's cancer drug was recommended for approval in Europe. The decision was made by a scientific ...

  • Reuters2 days ago

    EU regulators greenlight U.S. biotech Aveo's kidney cancer drug

    European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market. The European Medicines Agency (EMA) said experts at its Committee for Medicinal Products for Human Use (CHMP) had backed the oral, once-daily drug for marketing approval as a first-line treatment for advanced renal cell carcinoma, or kidney cancer. The drug was also backed for treating adult patients with advanced kidney cancer who met certain criteria and had received one prior treatment with cytokine therapy, the EMA said.

  • AVEO Reaches Enrollment Target in Pivotal Tivozanib Study
    Zacks3 days ago

    AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

    AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target